2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMaleMiddle AgedNeoplasm Recurrence, LocalPositron-Emission TomographyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease course
2022
Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions
Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyHumansMagnetic Resonance ImagingMaleProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk FactorsConceptsPI-RADS 3 lesionsHigher prostate specific antigen densitySignificant prostate cancerProstate-specific antigen densityPrior negative biopsyNegative biopsyMagnetic resonance imagingProstate cancerPSA densityValidation cohortEquivocal lesionsAntigen densityResonance imagingMultivariable logistic regression modelData System (PI-RADS) 3 lesionsMultiparametric magnetic resonance imagingElevated PSA densityMulti-institutional analysisDecision curve analysisProstate Imaging ReportingDetection of csPCaLogistic regression modelsMultivariable analysisSubsequent biopsyTraining cohortClinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer
Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.Peer-Reviewed Original ResearchMeSH KeywordsHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesWatchful WaitingConceptsActive surveillanceIndex lesionProstate biopsyProstate cancerMultiparametric magnetic resonance imagingData System version 2Low-risk CaPSurveillance prostate biopsyGleason grade groupMultivariate logistic regressionSignificant prostate cancerProstate Imaging ReportingReceiver operator characteristic curvePI-RADS 2Low-suspicion lesionsOperator characteristic curveMagnetic resonance imagingHigher PSADOnly significant variablePrimary outcomeMultivariable analysisSystematic biopsyRetrospective analysisBiopsy approachImaging Reporting